Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 12;75(14):2897–2906. doi: 10.1158/0008-5472.CAN-14-2860

Figure 5.

Figure 5

Decitabine modulates MEK/ERK pathway activation. A, change in activity of the MEK inhibitor, trametinib, after pre-treatment for nine days with decitabine in KRAS-mutant and KRAS-wild type ovarian cancer cell lines. B, KRAS-mutant ovarian cancer cell line, MCAS, was pre-treated with decitabine for three days, followed by co-treatment with decitabine and trametinib for three days (two biological replicates, mean ± SD). Data were normalized to the ATP levels (CTG) measured for the corresponding DMSO- or decitabine-treated controls (6 days). C, phosphorylation of MEK and ERK was probed by western blot after treatment with decitabine for six days in a KRAS-mutant (MCAS) and KRAS-wild type (RMGI) ovarian cancer cell line. Data is representative of two independent experiments.